Navigation Links
Awareness of Genzyme's Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected

EXTON, Pa., May 23 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Renvela report, the second in a multi-phase syndicated market research project tracking the launch of Renvela from baseline awareness through the first six months of product availability. The baseline report was published in December 2007. Wave 1 was fielded in April 2008, one month post Renvela launch, and provides quantitative information from 30 clinical Nephrologists and 30 Renal Dietitians (RDs) in the US, and qualitative information from a subset of 15 respondents in each group.

While virtually all Nephrologists and RDs are aware of Renvela, the next generation Renagel (sevelamer hydrochloride), the vast majority have not yet tried the new phosphate binder. Reimbursement is currently the biggest obstacle to use. Genzyme representatives seem to have increased their contact frequency compared to competitors in their promotion of this new product -- most often focusing on Renvela's similarity to Renagel but with fewer incidences of acidosis and better GI tolerability, according to Nephrologists and RDs. Renvela trials for the most part have been in patients switched from Renagel or naive to binder therapy, although depending on patient types, there are switches from competitive products. Each binder is associated with a variety of attributes and each is associated with unique concerns. Renvela is currently perceived to be the best choice for patients with metabolic acidosis.

Despite slower uptake than MDs and RDs predicted in the baseline research, Renvela share is expected to increase in the next six months among both dialysis and CKD patients.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. ( provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact Jennifer Robinson at (610) 363-3872 or

All company, brand, or product names contained in this document may be trademarks of their respective holders.

SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MultiVu Video Feed: Allergan, Inc. Partners With "Project Runway" Designer Kara Saun and Gen Art Fresh Faces In Fashion to Raise Awareness About Excessive Underarm Sweating
2. CDC Awards NATT Funding to Improve Blood Clot Awareness
3. The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies
4. Answers.coms WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month
5. SleepQuest Raises Awareness of Sleep Disorders
6. Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness
7. Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
8. Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
9. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
10. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
11. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... published their findings on what they believe could be a new and helpful ... the new research. Click here to read it now. , Biomarkers ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... Finland , June 9, 2016 ... National Police deploy Teleste,s video security solution to ensure the ... France during the major tournament ... data communications systems and services, announced today that its video ... Prefecture to back up public safety across the ...
Breaking Biology News(10 mins):